drugset / Trial / NCT05904015

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

NCT05904015

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of envafolimab combined with concurrent chemoradiotherapy in limited stage small cell lung cancer.

Timeline

Start
2023-08-01
Primary completion
2026-12-30
Completion
2027-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Envafolimab Monoclonal antibody 300 mg Subcutaneous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous

Indications